NYSE$COR

Cencora Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

Cencora reported a revenue increase of 7.8% year-over-year, with GAAP diluted EPS at $2.09 and adjusted diluted EPS at $3.80.

Cencora reported a strong second quarter with revenue increasing by 7.8% year-over-year to $68.4 billion. GAAP diluted EPS was $2.09, while adjusted diluted EPS increased by 8.6% to $3.80. The company raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.30 to $13.50.

  • Revenue increased by 7.8% year-over-year to $68.4 billion.
  • GAAP diluted EPS was $2.09, compared to $2.13 in the prior year.
  • Adjusted diluted EPS increased by 8.6% to $3.80, from $3.50 in the prior year.
  • Adjusted diluted EPS guidance raised to $13.30 to $13.50 for fiscal year 2024.

Headline financials

Total Revenue

$68.4B

Previous: $63.5B+7.8%
EPS

$2.09

Previous: $3.50-40.3%
Effective Tax Rate

9.8%

Previous: 16.4%-40.2%
Adj. Effective Tax Rate

20.9%

Previous: 19.0%+10.0%
Capital Expenditures

-$187M

Previous: -$179M-4.7%
Free Cash Flow

$234M

Previous: $257M-9.0%
Net Income

$421M

Previous: $435M-3.4%
Operating Income

$553M

Previous: $561M-1.3%
Gross Profit

$2.54B

Previous: $2.3B+10.6%
Cash & Equivalents

$2.07B

Previous: $1.54B+34.4%
Total Assets

$63.9B

Previous: $58.8B+8.7%
Stock-Based Comp

$28.2M

Previous: $23.5M+19.8%

Revenue & EPS history

Cencora · Revenue · Quarterly

$68.4B

Q2 2024+7.8%vs Q2 2023
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Forward guidance

Cencora updated its fiscal year 2024 financial guidance to reflect expected continued solid business performance for the full year and a higher effective tax rate and expected share count.

Tailwinds

  • Adjusted diluted earnings per share to be in the range of $13.30 to $13.50.
  • International Healthcare Solutions segment revenue growth to be in the range of 4 to 7 percent.
  • Adjusted consolidated operating income growth to be in the range of 9 to 11 percent.
  • U.S. Healthcare Solutions segment operating income growth to be in the range of 10 to 12 percent.
  • Weighted average diluted shares outstanding are expected to be approximately 201 to 202 million.

Headwinds

  • The Company does not expect exclusive COVID-19 therapy contributions for the balance of fiscal 2024
  • Adjusted effective tax rate to be approximately 21 percent.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-0.1%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.4%

Avg return

30 days after

48%

35 / 73 earnings

Positive

+7.8%

Q2 2019

Best reaction

-18.4%

Q2 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026-18.4%-16.6%-10.1%
Q1 2026-5.9%+0.4%-0.9%
Q4 2025+2.9%+5.8%-1.4%
Q3 2025-2.9%-0.6%+0.1%
Q2 2025+4.6%-4.3%-0.6%
Q1 2025+0.7%-2.1%+1.2%
Q4 2024+5.9%+6.5%+4.0%
Q3 2024+5.8%+4.4%+3.7%
Q2 2024-6.0%-6.3%-5.2%
Q1 2024+7.4%+6.2%+7.5%
Q4 2023+4.2%+4.7%+9.0%
Q3 2023+1.2%-1.3%-7.5%
Q2 2023+0.1%+0.7%+3.5%
Q1 2023-6.2%-8.6%-7.6%
Q4 2022+4.4%+3.1%+12.4%
Q3 2022-2.5%-1.5%+3.4%
Q2 2022+2.9%+4.4%-2.5%
Q1 2022+0.2%+1.3%+7.0%
Q4 2021-0.6%-2.8%-9.0%
Q3 2021-1.5%-2.8%+1.2%
Q2 2021-6.5%-2.1%-7.1%
Q1 2021+3.9%+1.8%-0.7%
Q4 2020-1.0%+4.8%-1.9%
Q3 2020-3.0%-1.6%-7.7%
Q2 2020+3.0%+3.6%+15.8%
Q1 2020-4.8%-2.0%-6.2%
Q4 2019+1.6%+1.0%+4.2%
Q3 2019+3.8%-3.5%-5.6%
Q2 2019+7.8%+5.5%+6.1%
Q1 2019+6.7%+9.2%+5.7%
Q4 2018-2.3%+0.3%-2.9%
Q3 2018+1.9%+5.0%+13.2%
Q2 2018-4.3%-5.1%-6.6%
Q1 2018+2.5%-2.9%+4.7%
Q4 2017-2.4%-2.2%+10.9%
Q3 2017-11.4%-12.0%-12.1%
Q2 2017+3.9%+5.9%+13.2%
Q1 2017+6.0%+6.8%+9.9%
Q4 2016+3.6%+3.1%+12.9%
Q3 2016+5.1%+4.5%+1.9%
Q2 2016-9.2%
Q1 2016-3.7%
Q4 2015-1.0%
Q3 2015-5.4%
Q2 2015+1.9%
Q1 2015+0.4%
Q4 2014+7.1%
Q3 2014+3.7%
Q2 2014-3.1%
Q1 2014-4.3%
Q4 2013+1.8%
Q3 2013-0.0%
Q2 2013-4.6%
Q1 2013-5.1%
Q4 2012-0.6%
Q3 2012+2.7%
Q2 2012-1.2%
Q1 2012+2.4%
Q4 2011-1.0%
Q3 2011-0.5%
Q2 2011+2.9%
Q1 2011+0.5%
Q4 2010-0.5%
Q3 2010-0.7%
Q2 2010+1.0%
Q1 2009-1.7%
Q1 2010+1.2%
Q4 2009-0.6%
Q2 2009-0.6%
Q4 2007-0.6%
Q3 2008-0.5%
Q3 2009-0.5%
Q4 2008-0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro